Neuromyelitis optica (NMOSD): vizsgálatok itt: Kína
30 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- No phaseTaking peopleRegistry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
- Where
- Beijing, Guangzhou, Henan, Shanghai, Sichuan, Wuhan
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT05966467 - 3. fázisTaking peopleA Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Where
- Guangzhou, Shanghai
- Életkor
- 2 év to 11 év
- People
- 8 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05199688 · EU 2023-507817-85-00 - 1. fázisTaking peopleThe Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
- Where
- Wuhan
- Életkor
- 18 év to 65 év
- People
- 69
- Run by
- Tongji Hospital
See details and how to joinNCT06620809 - No phaseTaking peopleHANDLE-a Real World Study on Satralizumab in NMOSD
- Where
- Shanghai
- Életkor
- 12 év and over
- People
- 100
- Run by
- Huashan Hospital
See details and how to joinNCT06829524 - 3. fázisTaking peopleEfficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Where
- Beijing, Chengdu, Dongguan, Jinan, Shanghai, Shijiazhuang, Taiyuan, Wenzhou, Wuhan
- Életkor
- 18 év to 130 év
- People
- 19
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07557420 - 2. fázisNot yet taking people in KínaEfficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
- Where
- Beijing
- Életkor
- 18 év to 74 év
- People
- 60
- Run by
- Peking University People's Hospital
See details and how to joinNCT07809724 - No phaseTaking peopleA Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 50
- Run by
- Junwei Hao, MD
See details and how to joinNCT07762872 - No phaseTaking peopleBiomarkers in Autoimmune Disease of Nervous System
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 50 000
- Run by
- Tongji Hospital
See details and how to joinNCT06502015 - 4. fázisNot yet taking people in KínaCrisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
- Where
- Beijing, Changchun, Chongqing, Harbin, Hohhot, Kunming, Shenyang, Ürümqi, Xi'an
- Életkor
- 18 év to 75 év
- People
- 110
- Run by
- Tang-Du Hospital
See details and how to joinNCT07699770 - 1. fázisNot yet taking people in KínaA Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
- Where
- Qingdao
- Életkor
- 18 év to 70 év
- People
- 18
- Run by
- The Affiliated Hospital of Qingdao University
See details and how to joinNCT07676266 - No phaseTaking peopleCohort Study on Neuroimmune Diseases in the Reproductive Age
- Where
- Guangzhou
- Életkor
- 20 év to 55 év
- People
- 100
- Run by
- Third Affiliated Hospital, Sun Yat-Sen University
See details and how to joinNCT07653984 - Korai 1. fázisNot yet taking people in KínaThe Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 18
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT07592754 - 3. fázisTaking peopleModified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
- Where
- Tianjin
- Életkor
- 18 év to 80 év
- People
- 198
- Run by
- Tianjin Medical University General Hospital
See details and how to joinNCT07420296 - 1. fázisTaking peopleSafety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 6
- Run by
- Tongji Hospital
See details and how to joinNCT07526493 - 2/3. fázisTaking peopleA Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- Where
- Beijing, Cangzhou, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Huizhou, Jinan, Jining, Kunming, Nanchang, Nanyang, Qingdao, Shenyang, Shenzhen, Shijiazhuang, Shiyan, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Xi'an, Xianyang, Yantai, Yongzhou, Zaozhuang, Zhengzhou, Zigong
- Életkor
- 18 év and over
- People
- 132
- Run by
- Shanghai Jiaolian Drug Research and Development Co., Ltd
See details and how to joinNCT06413654 - 4. fázisTaking peopleTherapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 200
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT07410039 - Korai 1. fázisNot yet taking people in KínaUniversal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 15
- Run by
- Tianjin Huanhu Hospital
See details and how to joinNCT07392528 - 1/2. fázisTaking peopleOfatumumab in AQP4-IgG Seropositive NMOSD
- Where
- Xi'an
- Életkor
- 18 év and over
- People
- 5
- Run by
- Tang-Du Hospital
See details and how to joinNCT05504694 - No phaseTaking peopleEfficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Where
- Xi'an
- Életkor
- 18 év to 75 év
- People
- 12
- Run by
- Tang-Du Hospital
See details and how to joinNCT07377305 - No phaseCsak meghívásosNormal Chinese Lifespan Brain Charts Initiative (NCLBCI)
- Where
- Beijing
- Életkor
- 6 év to 90 év
- People
- 10 000
- Run by
- Beijing Tiantan Hospital
See details and how to joinNCT06643858 - No phaseNot yet taking people in KínaProspective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)
- Where
- Xiamen
- Életkor
- 18 év and over
- People
- 4000
- Run by
- Xiamen Hospital of Traditional Chinese Medicine
See details and how to joinNCT07266051 - Korai 1. fázisTaking peopleUniversal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 12
- Run by
- Tianjin Huanhu Hospital
See details and how to joinNCT06939166 - No phaseTaking peopleMonoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
- Where
- Wuhan
- Életkor
- 18 év to 65 év
- People
- 200
- Run by
- Tongji Hospital
See details and how to joinNCT06885957 - 1. fázisTaking peopleA Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 30
- Run by
- RenJi Hospital
See details and how to joinNCT06249438 - No phaseTaking peopleProtein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder
- Where
- Guangzhou
- Életkor
- 18 év to 65 év
- People
- 144
- Run by
- Third Affiliated Hospital, Sun Yat-Sen University
See details and how to joinNCT06763848